Key Points
- Oncomatryx's antibody OMTX305 destroyed tumor-protecting fibroblasts in 15 patients with lung and ovarian cancer.
- The study showed that attacking the tumor microenvironment can kill cancer cells, supporting Oncomatryx's approach to treating solid tumors.
- Clinical trials will be needed to determine which patient profiles respond most strongly to OMTX305.
How Oncomatryx's Antibody Works
Oncomatryx, a Spanish biopharmaceutical company, has developed an antibody called OMTX305 that targets tumor-protecting fibroblasts. In a recent study published in Science Advances, OMTX305 showed promising results in destroying these fibroblasts and increasing cancer cell death in 15 patients with lung and ovarian cancer.
The study used tissue slices from freshly resected tumors from the patients, which were then cultured with the patients' own immune cells. The results showed that OMTX305 activated T cells, particularly those already inside the tumor, and directed them against cancer-associated fibroblasts. This led to an increase in the death of nearby tumor cells in some of the samples.
While the results are promising, the authors note that clinical trials will be needed to determine which patient profiles respond most strongly to OMTX305. The study's lead author, Meng Dong, suggests that the tumor's immune profile and PD-L1 expression may be potential indicators of response.
At a Glance
| Company | Oncomatryx Spanish biopharmaceutical company |
| Antibody | OMTX305 Bispecific antibody targeting tumor-protecting fibroblasts |
| Cancer Types | Lung and Ovarian Tumor types studied in the trial |
| Study | Science Advances Journal where the study was published |
Behind the Breakthrough: Oncomatryx's 15-Year Quest
Behind the Breakthrough: Oncomatryx's 15-Year Quest
Oncomatryx has been pursuing a unique approach to treating solid tumors for over 15 years, focusing on targeting the tumor microenvironment rather than the tumor cell itself. This approach is reflected in the development of OMTX305, which directs the patient's own T cells against tumor-protecting fibroblasts.
The study's results support Oncomatryx's approach and provide a potential new route to treating cancer. However, the company's founder and CEO, Laureano Simón, notes that more work is needed to determine which patient profiles respond most strongly to OMTX305.
What This Means for Cancer Treatment
What This Means for Cancer Treatment
The results of this study suggest that targeting the tumor microenvironment may be a promising new approach to treating cancer. However, more research is needed to determine the effectiveness of OMTX305 in clinical trials.
For patients with lung and ovarian cancer, this study provides hope for a potential new treatment option. However, it is essential to note that clinical trials will be needed to confirm the efficacy of OMTX305.
Comments 0